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Abstract
Epileptic encephalopathies represent a group of devastating epileptic disorders 
that appear early in life. They are characterized by pharmacoresistant generalized 
or focal seizures, persistent severe EEG abnormalities, and cognitive dysfunction or 
decline. The ictal and interictal epileptic discharges are age-specific and either are the 
main cause or contribute to cognitive deterioration in the idiopathic or symptomatic 
group, respectively. Despite choosing the most appropriate antiepileptic drugs for the 
seizure type and syndrome, the results are often disappointing, and polytherapy and/
or alternative therapy becomes unavoidable; in those cases, consideration should be 
given to the quality of life of the child and carers. In this chapter, we will discuss the 
clinical and electroencephalographic characteristics and evolution and management 
of age-related epileptic encephalopathies, recognized by the International League 
Against Epilepsy, as follows: early infantile epileptic encephalopathy (Ohtahara 
syndrome), early myoclonic encephalopathy, epilepsy of infancy with migrating focal 
seizures, infantile spasms (West syndrome), severe myoclonic epilepsy in infancy 
(Dravet syndrome), myoclonic-atonic epilepsy (Doose syndrome), Lennox-Gastaut 
syndrome, epileptic encephalopathy with continuous spike-and-wave during sleep, 
and Landau-Kleffner syndrome. Their clinical features, prognosis, etiologies, and 
treatment are presented and updated.
Keywords: electroclinical seizures, epileptic encephalopathy, pharmacoresistant 
epilepsy, epilepsy, electroencephalography
1. Introduction
The concept of epileptic encephalopathy (EE) is based on the clinical descriptions 
of some epileptic syndromes during the last century, such as West syndrome (WS) 
and Lennox-Gastaut syndrome (LGS). Delay in development in one, and intellectual 
disability in the other, was considered partly due to interictal epileptic discharges [1]. 
The idea that not only seizures but also apparently subclinical epileptic activity could 
affect cognitive functions was gaining strength in the scientific community related to 
epilepsy. According to this, the control of this epileptic activity could improve these 
deficits [1]. This notion was better profiled in the description of neuropsychological 
deficits related to continuous or sub-continuous paroxysmal activity during sleep, 
with the first description of the Landau-Kleffner syndrome (LKS) [2].
The definition of EE was better defined by Dulac in the 1990s and was incorporated 
into the proposed classification of the International League Against Epilepsy (ILAE) 
in 2001 [3]. In this proposal, the term EE was used for disorders in which “the epilepti-
form anomalies themselves are believed to contribute to the progressive disturbance of 
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brain function.” In 2006, Engel defined EE as disorders in which the evidence suggests 
the idea that neurological impairment depends on epilepsy and not on an underlying 
metabolic, degenerative, or encephalitic process, so that it excludes these progressive 
etiologies from the possible etiologies of EE [4]. Engel also emphasizes the importance 
of distinguishing between the deficits that are due to the cause of epilepsy, those that 
are due to pharmacotherapy, and those that are due to epilepsy itself.
The ILAE Working Group of 2010 pointed out the recognition achieved by the 
scientific community in relation to the EE [5]. The notion that epileptic activity 
itself may contribute to cognitive and behavioral deficiencies that exceed beyond 
what might be expected from causal pathology alone underlies the concept of 
EE. Deficits caused by epileptic discharges can be global or focal and can occur in a 
broad spectrum of severity.
In 2012, Capovilla proposed the term epileptogenic encephalopathy. They refer to 
progressive disorders of various etiologies that can cause deterioration and epilepsy, 
such as brain tumors, neurodegenerative or metabolic diseases, and presumed 
inflammatory or autoimmune conditions [1]. In epileptogenic encephalopathies, 
deterioration is independent of epilepsy, even if epilepsy could worsen the clini-
cal picture; in some cases, the same etiology can produce encephalopathy without 
epilepsy. This distinction is important for the treatment; in the EE the treatment 
must be aggressive. On the other hand, if the deterioration is due to the etiology, 
there is a risk of unjustified excessive treatment. It is known that drugs, especially in 
polytherapy, can aggravate the neuropsychological deficits in these patients.
2.  Neonatal epileptic encephalopathies: early infantile epileptic 
encephalopathy with suppression-burst pattern (Ohtahara syndrome) 
and early myoclonic encephalopathy (EME)
2.1 Overview
Early myoclonic epilepsy and early infantile epileptic encephalopathy  
(or Ohtahara syndrome) are age-dependent EEs that occur in the earliest stages of life. 
Although they share some clinical, electroencephalographic and prognostic character-
istics, they are distinguished by their clinical presentations and different etiologies [6].
In 1976, Ohtahara et al. report an epileptic syndrome that affected very young 
babies with a typical electroencephalographic pattern, and they called it “early 
infant epileptic encephalopathy with suppression-burst” [7]. Ohtahara observed 
that this disorder progressed frequently to West syndrome (WS) and then to a 
Lennox-Gastaut syndrome (LGS) [8]. Ohtahara syndrome (OS), as it has been 
called since the 1980s, has also been known for other terms, such as myoclonic 
epilepsy with neonatal onset, neonatal epileptic encephalopathy with periodic 
electroencephalographic bursts, and early myoclonic epileptic encephalopathy.
In 2001, the ILAE Classification and Terminology Working Group included both 
OS and EME within EEs [3]. Both syndromes are similar in terms of age of onset, a 
characteristic of suppression-burst EEG, and the presence of several types of super-
imposed seizures; due to this, their differentiation is difficult and often impossible 
at the beginning of the disease [9]. On the other hand, motor manifestations at this 
age are difficult to classify.
2.2 Seizures: symptoms and semiology
In both syndromes, seizures begin almost after birth, usually during the first 
month of life [9]. In OS, the most typical seizures are epileptic spasms and tonic 
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seizures, in groups or isolated [10]. In patients with hemispheric structural lesions, 
seizures can be unilateral or at least asymmetric. On the other hand, in the EME, 
myoclonic (axial, segmental, or erratic) seizures are more characteristic. The fre-
quency of seizures is flexible and can be almost continuous. Erratic and segmental 
myoclonus usually occurs in the first days [11]. In erratic myoclonus, the jerking 
seems to change arbitrarily from one area of the body to another, mainly in the face 
and extremities, although axial myoclonus could also appear. Subtle focal or clonic 
seizures may continue to myoclonus. Additionally, the complex motor manifestations 
that are associated with bursts of paroxysmal activity on the EEG are difficult to clas-
sify as spasms or myoclonus. Both conditions can present focal seizures commonly; 
these can be with deviation of the eyes, tonic posture, or hemiconvulsions; subtle 
attacks can also occur with autonomic phenomena, such as flushing or apnea [9].
2.3 Electroencephalography features
2.3.1 Background
The EEG may be normal at the beginning of the EME, which is why successive 
EEGs must be repeated to define the diagnosis. When the clinical presentation is 
complete, there is no temporal or spatial organization or physiological characteris-
tics in wakefulness or sleep [11].
2.3.2 Interictal abnormalities
The typical pattern is the suppression-burst (S-B); it consists of bursts of high-
voltage asynchronous delta or theta waves, interspersed with spikes and polyspikes 
from 150 to 350 μV that last from 1 to 6 seconds and alternate with low voltage 
(<10 μV) or complete suppression activity intervals of 2–5 seconds in duration [8]. 
In the EME, the bursts are shorter, and the suppression periods are much longer 
[11]; the S-B pattern in OS occurs in both wakefulness and sleep, while the S-B pat-
tern in EME, which usually is present only during sleep [9].
The S-B pattern may vary in configuration and the interhemispheric synchro-
nization of the bursts; they may predominate in one hemisphere, especially when 
associated with lateralized structural anomalies, such as focal cortical dysplasia 
or hemimegalencephaly [11]. During the suppression periods, focal epileptiform 
discharges can be observed [12].
The S-B pattern may persist beyond the first year of life, or it may progress to 
hypsarrhythmia between 3 and 6 months of age; it’s coinciding with the develop-
ment of epileptic spasms in the WS context [11]. The early transition to hypsarrhyth-
mia is more common in the OS, while in the EME the S-B can continue in the infancy 
until a transient evolution to hypsarrhythmia in the middle and late infancy [10]. 
There are reports of evolution to the slow spike-wave pattern characteristic of LGS.
2.3.3 Ictal EEG
During tonic spasms, EEG shows desynchronization with or without rapid 
activity [8]. By means of video-electroencephalography (video-EEG) with electro-
myographic recordings from deltoid muscles, we observe that each burst is to be 
associated with tonic contraction of variable duration [13]. The erratic myoclonus 
of EME habitually has no EEG correlate, whereas limb/axial myoclonus are usually 
associated with bursts of spikes and polyspikes.
Complex stereotyped movements that are difficult to classify as either spasms or 
myoclonias are also associated with bursts of activity. There is no correlation between 
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the duration of the burst and the type of seizure [11]. Focal seizures and subclinical 
phenomena are associated with focal discharges of spikes or sharp wave [8].
2.3.4 EEG differential diagnosis
A discontinuous EEG pattern with resemblances to S-B can be seen in neona-
tal hypoxic ischemic encephalopathy, but in this condition, the pattern is gener-
ally transient and can be reactive. Treatment for neonatal status epilepticus, such 
as midazolam, sufentanil, and fentanyl infusion, may exhibit a pattern evocative 
of S-B.
2.4 Etiology
The etiologies of OS are diverse, including specific genetic mutations, cortical 
brain malformations, mitochondrial disorders, nonketotic hyperglycinemia, and 
severe perinatal hypoxic-ischemic injury. On the other hand, EE vitamin-responsive 
disorders need to be ruled out as a potential underlying etiology; in certain cases the 
cause is unknown.
The most frequent genetic abnormalities linked with OS are aristaless-related 
homeobox (ARX) gene mutations at Xp22.13, cyclin-dependent kinase-like 5 
(CLDK5) (STK9) gene at Xp22, solute carrier family 25 [mt carrier, glutamate car-
rier-1/GC-1] member 22 (SLC25A22) gene at 11p15.5, STXBP1 (MUNC18-1) gene 
microdeletion at 9 q33.3-q34.11, KCNQ2 gene mutations, SCN2A gene mutations, 
and GABRA1 gene mutations [14].
EME is usually associated with inherited metabolic disorders, such as nonketotic 
hyperglycinemia, organic acidemias, Zellweger syndrome, and molybdenum cofac-
tor deficiency [15]. Until the report of Cohen in 2014, in two siblings with early 
myoclonic encephalopathy, born to consanguineous parents of Arab Muslim origin, 
a potential mutation of SLC25A22 should be considered in infants presenting as 
EME, severe microcephaly, and autosomal recessive inheritance with negative 
metabolic workup [16].
Several of the genes may manifest as phenotypes that overlap not only with OS 
and EME but also with other EEs such as West syndrome [14].
Box 1 shows differences between early epileptic encephalopaties [17].
EME OS
Clinical
Early myoclonus progressively becoming erratic, 
fragmented, and massive, followed by focal seizures 
and rarely tonic spasms
Clinical
Characterized by tonic spasms, focal 
seizures, and rarely massive myoclonus; this 
is never erratic
EEG
The S-B pattern is continuous in both awake and sleep 
states
EEG
The S-B pattern is limited or more distinct 
during sleep
Etiology
Structural brain abnormalities, a few metabolic, 
non-familial. Genes found: ARX, STXBP1, KCNQ2, 
and PNKP
Etiology
Cryptogenic, familial, and metabolic. Genes 
found: ErbB4 and SEC25A22
OS, Ohtahara syndrome; EME, early myoclonic encephalopathy; S-B, suppression-burst; ARX, aristaless-
related homeobox
Box 1. 
Differences between early infantile epileptic encephalopathy (EME) and Ohtahara syndrome (OS).
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2.5 Treatment and prognosis.
There is no specific treatment efficacious for these epileptic syndromes. For OS, 
adrenocorticotropic hormone (ACTH)/corticosteroids, vigabatrin, levetiracetam, 
zonisamide, phenobarbitone, rufinamide, and ketogenic diet should be tried. 
Resective surgery may be useful in cases of focal cortical dysplasia or hemimega-
lencephaly. Patients diagnosed as EME should receive a trial of pyridoxine. In cases 
with nonketotic hyperglycinemia, oral administration of ketamine, tryptophan, 
and dextromethorphan, in combination with benzoate, may improve the neurologi-
cal symptoms [18]. Vigabatrin and sodium channel blocker AEDs should be avoided 
in the myoclonic phase of EME.
Prognosis in both syndromes is very poor, and the response to treatment is 
very disappointing. About half of patients die within weeks or months from onset, 
and the others progress with severe neurological impairments. Two-thirds of the 
survived OS patients develop infantile spasms, around 3–7 months, and numerous 
advances to LGS after 1 year of age [18]. In EME, the erratic myoclonus will improve 
spontaneously with time, and then they will carry on having focal seizures, despite 
its treatment.
3. Infantile spasms (IS) and West syndrome (WS)
3.1 Overview
West syndrome (WS) was first described by Dr. WJ West of Tunbridge, United 
Kingdom, in 1841, in a letter addressed to the editor of The Lancet. West reports the 
characteristic clinical features in his own son. In 1952, Gibbs and Gibbs describe 
hypsarrhythmia, the characteristic electroencephalographic feature of WS [1]. 
WS is an age-dependent epilepsy that usually starts in the first year of life, most 
frequently between the first 3 and 9 months of life; however spasms can also affect 
older children but rarely beyond the age of 2 years. Even though the triad of epilep-
tic spasms in cluster, developmental regression, and hypsarrhythmia on the EEG 
defines WS, it is not always associated with the classical hypsarrhythmic EEG pat-
tern, and patients do not always have developmental regression at the beginning of 
the disease [19]. The recent ILAE classification included the term “epileptic spasms” 
(ES), rather than “infantile spasms,” when this seizure type is observed at other 
ages. Hypsarrhythmia can also be incidentally recorded in the absence of spasms.
3.2 Seizures: symptoms and semiology
ES are a seizure type, characterized by short-term muscle contractions that 
affect predominate proximal and truncal muscles which lead to abrupt flexion, 
extension, or mixed movements. According to EEG-EMG polygraphy records, an 
epileptic spasm reaches the full contraction more slowly than myoclonia but faster 
than a tonic seizure [20]. Usually, ES occurs in clusters but may be isolated. Clusters 
of ES increase progressively in frequency and intensity, reach a peak, and then 
gradually decline before they stop.
Some ES are limited to making only grimaces, deviation of the eye, and nod-
ding; they can also be subclinical; it’s called “subtle” ES. On the other hand, ES may 
be asymmetric, or asynchronous, concomitant with various focal manifestations 
that may implicate the limbs, head, or eyes; sometimes ES may express with com-
partmental and vegetative features. If ES is preceded or followed by, or interspersed 
with, focal seizures, it suggests a focal lesion [21].
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3.3 Electroencephalography
3.3.1 Background
Continuously abnormal during the wakefulness and sleep.
3.3.2 Interictal abnormalities
A typical interictal presentation in WS, hypsarrhythmia, refers to a high-voltage 
(hypsos = height), disorganized, and chaotic (without any discernible normal 
background rhythm = arrhythmia) EEG pattern. At onset, hypsarrhythmia may be 
present only during the drowsiness and light sleep, but it soon grows into profuse 
during the wakefulness.
Sometimes epileptic discharges appear to be focal or multifocal, however, 
without a rhythmic or organized pattern. This electrical manifestation is almost 
continuous, although in initial stages, background activity can be observed inter-
mittently. Hypsarrhythmia predominates in the posterior regions; rarely, posterior 
predominance is observed, especially after the first year of life [11]. This pattern of 
hypsarrhythmia reaches its peak in stage 1 of sleep, is less persistent in stages II and 
III of sleep (as multifocal spikes and sharp discharges), and disappears completely 
in REM sleep.
Different variants of hypsarrhythmia have been reported further than its typical 
presentation; these include (1) hypsarrhythmia with increased interhemispheric 
synchronization, (2) asymmetric hypsarrhythmia, (3) hypsarrhythmia with 
episodes of voltage attenuation, (4) hypsarrhythmia with a consistent focus of 
epileptic discharges or focal slowing, and others [22].
When the EEG shows atypical hypsarrhythmia, an underlying structural origin 
can be suspected; for example, predominating focal discharges or slow complexes 
could indicate a focal lesion, diffuse high-voltage theta-alpha activity may indicate 
lissencephaly or pachygyria, and persistent asymmetry or asynchrony may suggest 
a focal lesion or agenesis of the corpus callosum.
3.3.3 Ictal EEG
Ictal activity associated with ES includes a diffuse high-amplitude triphasic slow 
wave, a low-amplitude brief fast discharge, or a short-lasting diffuse flattening 
of ongoing activity [13, 20]. A transient disappearing or reduction of the hypsar-
rhythmic pattern could be seen during a cluster of ES. Patients with brain lesions 
may show an asymmetry of the ictal high-amplitude slow wave because of the more 
involved hemisphere. Focal or unilateral fast discharges directly preceding the high-
voltage slow wave are greatly suggestive of focal cortical lesion [11].
3.4 Etiology
WS etiology can be genetic, structural or metabolic, or unknown. Prenatal 
and perinatal etiologies explain more than 40% of the cases; they include central 
nervous system malformations, neurocutaneous syndromes (especially tuberous 
sclerosis), metabolic disorders, hypoxic-ischemic encephalopathy, central nervous 
system infections, and other acquired conditions [23].
Underlying etiology may be genetic, either chromosomal abnormalities or 
single-gene defects. The mutations in specific genes are ARX, GAMT, ALG13, 
CDKL5, SCN2A, STXBP1, SCN1A, ALG13, GABRB3, DNM1, SCN8A, MAGI2, 
ACADS, WDR45, and GABRA1 [23, 24].
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3.5 Treatment and prognosis
The key short-term aims of therapy are the rapid abolition of ES and the elimi-
nation of hypsarrhythmia. Effective treatment is associated with better outcome, 
at least in patients where the underlying pathology is not responsible for significant 
neurological deterioration. Therefore, children with WS, who are developmentally 
normal prior to spasms, continue to be normal after successful early treatment; 
on the other hand, children with WS, who have some cognitive problems prior to 
spasms, remain to have cognitive deficits, even after successful treatment related to 
the underlying pathology [25].
Other factors that contribute to unfavorable outcome are onset at 
age < 3 months, psychomotor retardation, existence of other seizure types, per-
sistence of abnormal EEG features, mild to gross neurologic deficits, significant 
computed tomography/MRI findings, and long duration of therapy. All unfavorable 
prognostic factors seem to relate to the underlying pathology; some symptomatic 
cases may develop autism or LGS [26].
With the exception of IS in the setting of tuberous sclerosis complex (TSC), 
there is relatively broad consensus that hormonal therapy is the most effective class 
of initial treatment for IS [27]; but the best agent, dose, and length of treatment are 
not clear. The most studied medications are natural adrenocorticotropic hormone 
(ACTH, a 39 amino acid peptide), synthetic ACTH (sACTH, a truncated peptide 
spanning the first 24 N-terminal residues), prednisolone, and prednisone (the 
prodrug of prednisolone).
The highest short-term response rates (freedom from ES and hypsarrhyth-
mia on treatment day 14) have been observed with ACTH administered at high 
dose (150 U/m2 body surface areas per day, divided into two daily doses) [28]. 
Although some authors reported that short-term response was far superior with 
this regimen of ACTH in comparison to prednisolone at dose of 2 mg/kg/day 
[29], a sequence of studies has suggested that higher dose regimens of pred-
nisolone are as effective as ACTH. In the UKISS study, no difference in response 
rate between prednisolone (40–60 mg/day) and a “moderate” dose of sACTH 
(0.50–0.75 mg on alternate days) was observed, although treatment allocation 
was not randomized [30]. Likewise, in a debatably underpowered retrospective 
analysis, Kossoff and colleagues reported that efficacy of high-dose prednisolone 
(40–60 mg/day) was similar to historical experience with high-dose natural 
ACTH [31]. In other relatively small study evaluating short-term efficacy of very 
high-dose prednisolone (8 mg/kg/day; max 60 mg/day) followed by high-dose 
natural ACTH in prednisolone nonresponders, the EEG-confirmed response 
to prednisolone (63%) was analogous to the reported ACTH response in most 
current studies [25].
More recently, in a large-scale prospective observational study led by the 
National Infantile Spasms Consortium (United States) without randomized treat-
ment distribution, Knupp and colleagues reported that response rates to natural 
ACTH (most with high-dose protocol; 150 U/m2/day) and oral corticosteroids 
(most with high-dose prednisolone; 40–60 mg/day) were statistically indistinct 
[32]. In the only modern randomized controlled trial comparing high-dose prednis-
olone (40–60 mg/day) with moderate-dose sACTH (0.5–0.75 mg on alternate days), 
Wanigasinghe and colleagues found that response to prednisolone was superior, 
though the response rate to sACTH was inexplicably low [33].
Given the cost of a typical course of ACTH exceeds 100,000 USD, a typical 
course of prednisolone costs less than 100 USD; many of treatment protocols for 
WS begin with prednisolone/prednisone and leave ACTH as an alternative for 
patients without response to this drug.
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All hormonal therapies exhibit similar—and important—adverse event profiles. 
The main risk is immunosuppression, which can be severe and potentially lethal, 
as well as hypertension, with the potential to yield congestive heart failure [34]. As 
such, avoidance of infectious contacts and screening for asymptomatic hyperten-
sion are key safety measures to be endorsed during any course of hormonal therapy. 
In addition, most clinicians prescribe antibiotic prophylaxis for pneumocystis 
pneumonia, screen for asymptomatic hyperglycemia, monitor serum potassium 
given modest risk of hypokalemia, and also screen for adrenal or pituitary insuf-
ficiency after a course of hormonal therapy.
Vigabatrin (VGB) is an irreversible inhibitor of γ-aminobutyric acid (GABA) 
transaminase, with proven efficacy in the treatment of IS in several random-
ized, controlled trials [35, 36]. Nevertheless, short-term response rates to VGB 
are considerably lower in comparison to the hormonal therapies. With respect to 
long-term outcomes, the superiority of hormonal therapy is not as clear [37, 38]. 
Although a large-scale trial of VGB versus high-dose hormonal therapy has not 
been undertaken in a TSC cohort, several studies indeed suggest that response 
to VGB is substantially higher among patients with WS associated with TSC in 
comparison to patients with other etiologies [39–41]. There is broad consensus 
that patients with IS in the setting of TSC should receive first-line treatment with 
VGB [27].
Overall, VGB is moderately effective (and highly effective in the setting of 
TSC) and confers moderate risk. The threat of visual field loss is relatively low and 
perhaps diminished by short courses of therapy; the risk of reversible and habitu-
ally asymptomatic MRI toxicity is moderately high and dose-dependent [41].
The hypothesis that combination therapy is superior to either therapy alone 
was proven in the International Collaborative Infantile Spasms Study (ICISS) 
[42], in which the investigators randomized new-onset patients with IS to receive 
either hormonal therapy (prednisolone or sACTH) alone or in combination with 
VGB. The combination therapy group exhibited superior response rates with 
respect to clinical outcome (parent-reported freedom from ES on days 14–42), 
electroclinical outcome, and time to cessation of ES.
A minority of children with IS are good candidates for surgical resection [43]. 
The etiologies best suitable to surgical resection include cortical dysplasia, cortical 
tubers in TSC, and various acquired structural lesions, for example, unifocal stroke 
or hemorrhage. The role of nonresective surgical approaches (e.g., corpus calloso-
tomy) is not well established in these patients [43].
There are rare occasions in which a specific metabolic etiology of IS prompts 
a specific therapeutic intervention, either as an alternative or adjunct to first-line 
therapy [44]; the most notable examples include pyridoxine (vitamin B6) depen-
dency (treated with pyridoxine or leucovorin), pyridoxal-5-phosphate deficiency 
(treated with pyridoxal-5-phosphate), glucose transporter type 1 (Glut1) deficiency 
(treated with the ketogenic diet), and nonketotic hyperglycinemia (ameliorated to 
some extent by sodium benzoate and other interventions to promote central glycine 
clearance) [45].
Other treatments are supported by very limited reports of efficacy. It includes 
traditional antiseizure drugs such as topiramate, zonisamide, valproic acid, 
felbamate, and benzodiazepines clonazepam and nitrazepam. Among nonphar-
macologic therapies, numerous studies suggest substantial efficacy for treatment 
of IS with the ketogenic diet; most of these are retrospective, and none has utilized 
placebo controls or unbiased outcome assessment. Prognosis depends on etiology 
and is better in children without apparent structural cause. In nearly half of the 
patients, WS evolves into LGS or multifocal epilepsies.
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4. Severe myoclonic epilepsy in infancy (Dravet syndrome)
4.1 Overview
Severe myoclonic epilepsy of childhood was described in 1978 by Charlotte Dravet 
and included among epileptic encephalopathies in the 2001 proposal [3]. However, 
the acceptance that DS is a channelopathy of the SCN1A gene, as well as the presence 
of neurological deterioration in the early stages of the disease, has questioned whether 
the deterioration is really due to epileptic seizures or due to channelopathy [46].
Estimated prevalence of Dravet syndrome (DS) is about 1% of epilepsy syn-
dromes in infancy and childhood, being more frequently in male. According to 
different descriptions of the natural course during of DS childhood, two phases have 
been identified: early phase (first year of life) and a steady phase (from 2 to 5 years 
of life); the electroclinical features are different between these phases. Early phase is 
characterized by long hemi- or generalized convulsive seizures, typically related with 
fever, while in the steady phase, seizures that predominate are myoclonic seizures 
(MS), atypical absences, and complex partial seizures (CPS); also, events of noncon-
vulsive status may occur. Cognitive development slows down progressively causing 
moderate/severe intellectual disability generally after the age of 4–5 years. Most 
patients develop ataxia, pyramidal signs, and hypotony, which persist to adulthood.
Seizure behavior should vary in time; association between seizures and fever 
may be absent; also CPS and MS may begin in the early phase. Diagnosis of DS 
may be delayed because of the variability in evolution, the seizure polymorphism, 
and the non-specific EEG features. Long-term prognosis is always bad, pharmaco-
resistance is the rule, and most patients go on severely cognitively impaired.
4.2 Seizures: symptoms and semiology
The typical picture is previously healthy children who begin with seizures in 
the first year of life; its seizures should be unilateral or generalized convulsive 
(clonic or tonic-clonic), are commonly prolonged (more than 10 min), and could 
be progressed into status epilepticus (SE). Seizures are usually triggered by fever, 
or occur after immunization, but may also be afebrile. In the second or third year of 
life, other types of seizure, generally afebrile, can occur [47] in the absence of MS, 
which starts later [48].
The seizure pattern changes over time; SE is the most problematic through the 
first 2 years of life and decreases in frequency after 5 years of age. In early childhood, 
frequent nonconvulsive seizures may negatively impact neurodevelopment. In the 
adolescent and adult years, brief but frequent nocturnal generalized convulsive sei-
zures are the most common and place the patient at risk of sudden unexpected death 
in epilepsy (SUDEP). The details of seizures observed in DS are described then:
A. Convulsive seizures
1. Unilateral with clear hemiclonic or tonic convulsions that may alternate sides 
in the same patient can offer a significant sign to early diagnosis.
2. Generalized tonic-clonic seizure (GTCS).
3. Falsely generalized (FG) and unstable seizures. FG are bilateral convulsive 
with asymmetric clonic or tonic movements and postures, at times predomi-
nating on one side or changing sides during the seizure.
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B. Focal seizures, commonly CPC, are accompanied with autonomic features like 
pallor, cyanosis, respiratory changes, and drooling and oral automatisms, with 
eyelid or distal jerks. These seizures are short (few minutes) but can progress 
into a unilateral or generalized motor seizure.
C. Myoclonic seizures (MS) should manifest like massive axial movements with 
falls or as a few jerks; erratic myoclonias are not rare.
D. Atypical absences (AA) could appear frequently linked with a myoclonic 
component.
E. Nonconvulsive status epilepticus (NCSE) or obtundation status is prolonged 
episodes (hours or days) of diminishing of consciousness with loss of contact 
or variably reduced responsiveness and somnolence, with erratic or seg-
mental myoclonus. This NCSE may be initiated, punctuated, or terminated 
by GTCS or be combined with axial myoclonic, myoclonic-atonic, or clonic 
seizures.
F. Tonic seizures are rare and may be triggered by intermittent photic stimulation 
(IPS), visual patterns, hot water immersion, and physical effort.
Sensitivity to photic or pattern stimulation is noted in approximately 40% of 
patients, particularly in younger children.
Worsening of seizures or SS may be provoked by blocking sodium channels 
AEDs, such as carbamazepine, phenytoin, lamotrigine, and vigabatrin.
In adults, seizures are more frequent during sleeping, especially long-lasting 
clonic seizures or short tonic-clonic seizures, while MS, AA, and focal seizures have 
a tendency to remit.
4.3 Electroencephalography
EEG abnormalities are non-specific, but interictal EEG is useful for differential 
diagnosis; however sequential EEG recordings may show the  evolution of DS, 
whereas ictal recordings with EMG polygraphy document seizure polymorphism [11].
4.3.1 Background
In wakefulness state background activity is normal at onset, despite the fre-
quent seizures; diffuse or asymmetric slowing may be seen if EEG is performed 
immediately after a seizure or may remain on for a few days. During sleeping 
normal patterns, initially after the first year, there is usually a gradual slowing of 
the background activity, more obvious if seizures are frequent. Physiological sleep 
phenomena and organization mostly remain conserved, except numerous noctur-
nal seizures occur.
4.3.2 Interictal abnormalities (IA)
It may be present at the beginning (22% of patients) and grow during the evo-
lution (77%) [48]. Generalized focal and multifocal abnormalities, spikes, and 
spike-wave or polyspike-wave discharges, symmetric or not, predominate over 
the frontal and central areas, but occur over the temporal and occipital areas, too. 
IA is typically greater during sleeping [48, 49]. The evolution of the EEG aspects 
with age is not always similar and being dependent on the number and duration 
of seizures.
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4.3.3 Ictal EEG
• Unilateral seizures. The ictal discharge is characterized by rhythmic (2–3/
second) bilateral slow waves of higher amplitude over the hemisphere contra-
lateral to the clinical manifestations and intermixed with 10/second recruiting 
rhythms. In others, the EEG pattern can onset over the frontal or frontal-cen-
tral regions of one hemisphere, or with bilateral asymmetric onset, but always 
predominant over the frontal areas.
• Falsely generalized and unstable seizures. In this type of seizures, the EEG 
discharge is of bilateral symmetric or asymmetric onset with a slow spike, 
occasionally followed by a brief attenuation, and fast activities intermixed 
with slow waves. Whereas, the ictal discharge change topographically in a same 
seizures, in unstable seizures [47].
• In CPS ictal EEG consists of a rhythmic sequence of fast polyspikes inter-
mixed with theta activity during the last part of the seizure, involving the 
temporal-parietal-occipital region of one hemisphere for the duration of the 
seizure [47].
• MS are accompanied by generalized spike or polyspike-wave discharges at 3 Hz 
or more, lasting 1–3 seconds and of higher voltage over the central-parietal areas.
• AA are linked with generalized regular or irregular spike-wave discharges at 
2–3.5 Hz, lasting 3–10 seconds.
• In obtundation status EEG background activity is substituted by diffuse delta 
slow waves, superimposed with multifocal spikes and spike-waves, sharp 
waves, and generalized spike-and-wave discharges preponderating over 
frontal-central areas.
• Tonic seizures are associated with diffuse discharges of polyspikes at 8–9 Hz [15].
4.4 Etiology
DS is a channelopathy due to mutation in the SCN1A gene which encodes the 
alpha 1 subunit of the voltage-gated sodium (Nav1.1) channel reported in 80% 
of patients [50]. Almost half of SCN1A mutations are truncations, and most DS 
SCN1A mutations are de novo [51]. SCN1A mutations are not pathognomonic of 
DS; it could be observed in a spectrum of febrile epilepsy syndromes, which ranges 
from genetic epilepsy with febrile seizures plus (GEFS+) to DS. The mutations in 
the SCN1A gene also constitute a risk factor for SUDEP by causing cardiac and 
respiratory dysfunctions [52]. Another gene implicated in DS is GABRA1 [53].
4.5 Treatment and prognosis
The aim of treatment in patients with DS is reducing seizure frequency, mini-
mizing comorbidities, limiting antiepileptic drug toxicity, and avoiding seizure-
related injury and SUDEP [54]. A greater degree of cognitive and behavioral 
impairment has been associated to higher frequencies of seizures [55, 56].
It is prominent that seizures are triggered by hyperthermia and less frequently 
by photosensitivity or pattern sensitivity; thus antipyretics for fever, minimizing 
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warm baths or exercising on warm days, and avoiding photosensitivity triggers are 
recommended [54].
Sodium channel-blocking drugs such as carbamazepine, oxcarbazepine, lamotrig-
ine, and phenytoin should also be avoided because they can aggravate seizures.
Valproic acid, clobazam, topiramate, levetiracetam, and stiripentol are the drugs of 
choice. Stiripentol combined with valproic acid and clobazam, as well as topiramate, 
give promising results [54, 57, 58]. The ketogenic diet is an alternative with good results 
for several patients, achieving a reduction of the seizures by 50% or more [59, 60].
The prognosis for children with DS is poor; the complete cessation of epileptic 
seizures is not achievable in these patients. Since the onset of disease, the neurologi-
cal status worsens, and about 10–20% of afflicted children will die prematurely 
[61, 62]. Early mortality, sometimes due SUDEP, occurs in about 10% of patients. 
However, the outcome, in at least some children, improves with early diagnosis and 
appropriate therapeutic intervention.
5. Epilepsy of infancy with migrating focal seizures (EIMFS)
5.1 Overview
EIMFS, previously called malignant migrating partial seizures of infancy, is a rare 
and severe condition describe in 1995 [63]. EIMFS is characterized by focal “migrat-
ing” or “random” seizures beginning within the first 6 months of life, severe global 
developmental delay, and acquired microcephaly. Epilepsy is highly pharmacoresis-
tant. At onset brain MRI is typically normal, but later it may show delayed myelination, 
thin corpus callosum, and cerebral atrophy [64]. Patients with intractable seizures have 
a progressive deterioration with major axial and limb hypotonia, loss of visual contact, 
and loss of other motor and social skills. Pyramidal and/or extrapyramidal features 
with athetotic movements may appear; about 18% of the patients died [65].
De novo KCNT1 mutations have been reported in about 50% of patients with 
sporadic EIMFS [64–66].
5.2 Seizures: symptoms and semiology
It is accepted that the natural history of the EIMFS goes through three distinct 
phases [63]. The first phase starts in the first 6 months of life and lasts a few weeks 
or months; patients have sporadic seizures with frequency every few weeks or 
months. Seizures used to be focal motor with quick generalization or associated 
with autonomic features like apnea, flushing, or cyanosis [63, 67]. The second 
phase, called “stormy phase,” arises between 1 and 12 months; seizures become 
more frequent, occurring in clusters several times a day or being practically con-
tinuous for several days. Seizure consists of lateral deviation of the head and eyes, 
twitches of the eyelids, unilateral clonic or tonic jerks of one or both limbs, apnea, 
flushing and/or cyanosis of the face, chewing movements, and secondary tonic-
clonic seizures [68]. Additionally, clinical manifestations may be “subtle” or absent 
even with the long duration of seizures.
The age at onset of the third phase is variable, from the end of the first year to 
the fifth year of age. This phase is typically seizure-free, even if interposing illnesses 
can trigger recurrent seizures or SS. Some patients can evolve to a WS [63, 65].
Migrating focal seizures (MFS) are seizures which occur usually in clusters that 
last for a few days and are then followed by a few weeks or months of recovery. 
Within a cluster, seizures are very frequent and may even extend to SS. Clusters 
increase in frequency within the first 2 years of life.
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5.3 Electroencephalography
5.3.1 Background
EEG is usually normal during the first months apart from slowing for many 
hours after long-lasting seizures. As the disease progresses, background activi-
ties become gradually diffusely slower with decline of physiological features. 
Activity may show alternating asymmetries, with slow activity that change from 
one hemisphere to another [63]. In seizure-free periods, sleep and wakefulness 
are obviously differentiated; nevertheless sleep spindles are rare, asynchronous, 
and asymmetric.
5.3.2 Interictal abnormalities
Interictal abnormalities are usually absent at onset; spikes rapidly grow in 
frequency and develop multifocal within a few months; multifocal spike-and-wave 
activities do not show any specific pattern and are not activated in sleep.
5.3.3 Ictal EEG
Epileptic discharges (ED) sequentially involve different areas of the brain, 
such as describing a random migration, without a specific pattern. The ictal 
pattern is characterized by rhythmic monomorphic activity in the alpha-theta fre-
quency range, although delta waves, spikes, and spike-waves can also be observed. 
It is common for epileptic activity to remain limited to one region for a period of 
time and then decrease in frequency until stop, with a tendency to progressively 
involve an adjacent area. ED is continued with slow postictal activity without 
prolonged voltage decrement [63, 68]. When epileptic seizures are frequent, 
ED changes from one region to another and from one hemisphere to another so 
that consecutive focal epileptic discharges overlap resulting in a continuous and 
changing multifocal ictal activity and a very complex epileptic status pattern [11].
5.4 Treatment
Migrating partial seizures are usually refractory to pharmacologic treatment 
though some cases have responded to bromide (60–80 mg/kg/day), with a termina-
tion of the seizures for several months after almost 3 weeks of therapy [69]. Even so, 
one should be aware of a potential bromoderma tuberosum, which could be appear-
ing with high doses of potassium bromide therapy [70]. Intravenous levetiracetam 
(60 mg/kg) rapidly interrupted migrating partial status in two children with a good 
tolerability and safety [71]. Other successful treatments include a combination of 
sodium bromide, stiripentol, and levetiracetam [72], rufinamide and acetazolamide 
[73, 74], and stiripentol associated with clonazepam.
6. Epilepsy with myoclonic-atonic seizures (EMAS) or Doose syndrome
6.1 Overview
In 1970, Herman Doose reported seizures in 51 previously normal children 
between 1 and 5 years of age described as myoclonic and astatic, frequently combined 
with absences and GTCS and tonic seizures [75]. Doose suggested a genetic etiology 
[76] and later refined his criteria and emphasized that tonic seizures are rare [77].
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In 1989, the ILAE recognized the syndrome of myoclonic-astatic epilepsy with a 
genetic predisposition, and in 2010 the term changed to “epilepsy with myoclonic-
atonic seizures” (EMAS). Features that define EMAS are (1) normal development 
previous to the start of seizures; (2) onset between 7 months and 6 years of age, 
of myoclonic, myoclonic-atonic, or atonic seizures; and (3) EEG with generalized 
spike or polyspike-and-wave discharges.
EMAS represents 1–2% of cases with childhood epilepsy and shows a vari-
able clinical course and age-dependent spectrum. Onset peaks at about 3 years 
and is more prevalent in boys, ratio about 2:1. A long-term follow-up study 
showed a common evolution which was classified, according to the definitive 
seizure outcome, into favorable, intermediate, and unfavorable forms [78]. 
Cumulative percentage remission reached 40% within 6 months, 63% within 
1 year, and 89% within 3 years after seizure onset [78]. Even in children with a 
favorable clinical course, seizures can be initially pharmacoresistant, sometimes 
demanding additional ACTH or ketogenic diet; in unfavorable patients, epilepsy 
remains refractory to treatment with the occurrence of long-lasting episodes of 
NCSE. Cognition is habitually normal during the first months of the disease, 
although patients are often severely hyperkinetic; intellectual outcomes range 
from favorable to unfavorable [79, 80].
6.2 Seizures: symptoms and semiology
The main seizure types range from myoclonic to atonic. MS, atonic seizures 
(before called astatic), and myoclonic-atonic seizures typically occur a few days or 
weeks after the onset of GTCS or clonic seizures.
It is common for the first seizures to be clonic seizures or GTCS, which occur 
in normal children; sometimes they can be preceded by febrile seizures (FS). In 
a few months, the frequency of crises increases gradually and AA may appear. 
Nonconvulsive SS may be of myoclonic-atonic, myoclonic, or AA type and may 
be resistant to treatment. Some patients with a poor outcome may have brief tonic 
seizures.
The types of seizures observed in EMAS are:
1. Epileptic drop attacks or seizures that cause falls, which can be of three differ-
ent types taking account the postural change, the temporal sequence of falling, 
and EMG polygraphy.
• Myoclonic flexor seizures with sudden flexion or extension of the head and 
trunk.
• Myoclonic-atonic seizures with initial change as the myoclonic flexor type, 
but following falling is produced by loss of muscle tone.
• Atonic seizures with sudden slumping or collapsing to the floor as a result of 
transient loss of muscle tone.
2. Generalized clonic seizures occur during both wakefulness and sleep. The 
clonic component commonly appears as the repetition of massive MS. Clonic 
movements habitually increase in frequency and may become very rapid 
resulting in a “clonic vibratory” seizure that usually ends with gradually 
decreasing frequency of the clonic jerks.
3. GTCS, in which clonic component is preceded by a tonic phase lasting a few 
seconds.
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4. Some patients may have prolonged recurrent AA with associated blurring of 
consciousness and often random segmental myoclonus or head nodding.
5. NCSE which consists of a cluster of myoclonic-astatic, MS, or AA. Clinically, we 
observe loss of contact or somnolence. Patients may have salivating and speech 
trouble ranging from dysarthria to mutism. Sometimes, erratic myoclonus in 
the face, the upper limbs, the eyelids, mouth, tongue, and fingers should be 
observed, associated with ataxic, hypotonia, tremor, and difficulty in walking.
6. Generalized tonic seizures with or without few clonic components occur dur-
ing sleeping. When predominant, these seizures are associated with unfavora-
ble outcome; they are resistant to treatment. When the tonic phase is preceded 
by a myoclonic jerk, seizures are termed “myotonic.”
6.3 Electroencephalography
6.3.1 Interictal background
Background activity is normal at the onset of the disease. A characteristic 
4–7-Hz diffuse theta rhythm, usually predominating over the central-parietal areas 
(central theta waves), is often present, intermixed with normal waking activi-
ties and increasing during the drowsiness. In some children, background may be 
diffusely slow. During sleeping, physiological features are usually seen at the onset, 
while diffuse slowing with loss of sleep architecture can occur during the evolution, 
mainly in the severe forms of the spectrum [11].
6.3.2 Interictal abnormalities
In wakefulness there may be no epileptiform discharges. If this is present, 
generalized spike-waves discharges are at 2–3 Hz, predominant over the frontal-
central areas. They may show not consistent asymmetries between the hemispheres. 
Focal or multifocal spikes may also be present; these are rarely abundant and may 
predominate on one side, but not consistently so, and are not associated with focal 
slowing [11]. During sleeping, focal and generalized spike-wave discharges may 
increase and acquire a typical polyspike component.
6.3.3 Ictal EEG
Generalized bilaterally synchronous single or multiple spike-and-wave dis-
charges with 2–4 Hz frequency are commonly associated with all three seizures 
types that produce drop attacks, although spike-wave discharges are briefer for 
myoclonus.
The EMG correlate of the jerk is a burst of muscle activity lasting 100 ms; 
this is followed by a post-myoclonic silent period of EMG inhibition that lasts for 
60–500 ms, which is synchronous for the recorded muscles and time-locked to the 
onset of the slow wave [78]. Both the brisk jerk and the post-myoclonic silent period 
concur to produce the typical drop.
AA corresponds of generalized irregular spike-wave discharges at 1.5–3 Hz. During 
NCSE, EEG shows no normal background activity, is characterized by diffuse and 
irregular spikes and slow waves persisting continuously throughout the episode, and is 
in combination with erratic myoclonus recorded on the EMG. Generalized tonic seizures 
correspond to burst of generalized spikes during sleep and eventually wakefulness.
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6.4 Etiology
Patients with Doose syndrome have probably a multifactorial inheritance, some 
of the first to be diagnosed with SCN1A mutations, but others have also been found 
to have sodium channel subunit beta-1 (SCN1B) and gamma-aminobutyric acid 
receptor subunit gamma-2 (GABRG2) mutations. However, these genes have not 
been found consistently in sporadic cases [79].
6.5 Treatment
Ethosuximide is reported to be one of the more effective antiepileptic drugs 
(AED), especially when absence seizures are the primary seizure type. Valproic 
acid and lamotrigine are also beneficial; however, lamotrigine probably cause 
paradoxical worsening in individuals for whom myoclonic seizures are prominent 
[79]. Levetiracetam and zonisamide have been anecdotally used and may be helpful 
[23]. The ketogenic diet is a widely reported therapy for Doose syndrome and may 
be the most efficacious treatment; expert consensus guideline for optimal use of 
the ketogenic diet listed Doose syndrome as one of the principal indications for 
this treatment [79]. Seizure remission has been reported even without changes to 
medication, which suggest that spontaneous remission of seizures does occur.
7. Lennox-Gastaut syndrome (LGS)
7.1 Overview
LGS is an electroclinical syndrome defined by the Marseille School between 
1966 and 1972 but was first reported by Lennox and Davis as an epilepsy starts in 
childhood and characterized by diffuse slow spike-waves (SSW) at <2.5 Hz and sev-
eral types of seizures including tonic seizures, atypical absences, and “drop attacks” 
[81]. The electroclinical description proposed by Beaumanoir and adopted by the 
ILAE Classification Commission in 1989 concerns 2–4% of childhood epilepsies 
and affects boys more frequently than girls [81]. In about 70–75% of patients, LGS 
is associated with a variety of inherited or acquired structural anomalies or chromo-
somal disorders, whereas in the other 25–30%, there is no identifiable etiology [82]. 
Electroclinical phenotype is similar in spite of the different etiologies because of a 
common underlying mechanism [83]; functional neuroimaging has indicated that 
epileptic activity in LGS recruits widespread areas of association cortex and that 
tonic seizures are expressed through the reticular formation of the pons [84]. Other 
epileptic syndromes like frontal epilepsies with secondary bilateral synchrony, 
EMAS, DS, late-onset ES, atypical benign partial epilepsy of childhood, and ring 
chromosome 20 epilepsy syndrome are the differential diagnoses; thus, an exhaus-
tive evaluation of the medical history along with an EEG during the wakefulness 
and sleep is very important for the accurate diagnosis of the syndrome.
7.2 Seizures: symptoms and semiology
Seizures start from 1 to 10 years but more frequently between 1 and 8 years; 
however, onset may occur in younger or older ages, even into adulthood. LGS may 
follow other types of epileptic syndromes, such as focal epilepsies, OS, and WS.
Diagnosis of LGS requires the following features: (1) many types of seizure, but 
inevitably include tonic seizures (TS) and atypical absences (AA), (2) cognitive 
impairment, and (3) typical interictal and ictal EEG patterns.
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TS are mandatory for the diagnosis of LGS; they are diurnal and nocturnal, 
facilitated in NREM sleep, and typically occur in clusters. TS consist of sudden 
flexion of the neck and body, raising of the arms in flexion or extension, extension 
of the legs, and contraction of the face muscles. It continuing of the eyes and auto-
nomic manifestations (apnea and facial flushing tachycardia), and can culminate 
as diffuse tremor (rapid, small-amplitude jerks affecting the whole body). They are 
axial and involve typically the proximal parts of the limbs, symmetrically or with 
unilateral predominance. TS can produce sudden falling, associated or not with 
brief loss of consciousness; the distal limb muscles are relatively spared.
AA is the second most common seizure, present in about 75% of patients. 
The main clinical manifestation is a brief lapse in consciousness, although some 
awareness may be preserved [82]; they are subtle and difficult to recognize 
without concurrent formal assessment of cognition and responsiveness. They are 
of long duration with the EEG discharge lasting >20 seconds, but their onset and 
termination are not always clinically discernible. Associated clinical features may 
include eyelid and mouth myoclonias and a decrease in muscle tone that may lead 
to a fall.
“Drop attacks” (sudden falls) are also frequent, affect 30–60% of patients, 
and are habitually related with a brief tonic seizure or an epileptic spasm [81]; the 
definition of seizure type that cause sudden falls most be requiring Video-EEG and 
polygraphic recording.
Drop attacks, and other types of seizures observed in LGS, are not specific to this 
syndrome; these are tonic-clonic, focal, myoclonic, and myoclonic-atonic. Episodes 
of SE may occur in about 60% of patients, consisting of alteration of consciousness 
with continuous SSW, and may be linked with serial tonic seizures [83].
7.3 Electroencephalography
7.3.1 Background
EEG is variable depending on etiology (structural, chromosomal, or idiopathic) 
and age, ranging from almost normal to, most often, poorly structured without 
physiological features and generally altered by continuous interictal abnormalities.
7.3.2 Interictal abnormalities
Generalized interictal features during the wakefulness and sleep are mandatory 
for diagnosis of LGS [11].
In wakefulness, high-amplitude, diffuse, and synchronous SSW at 1.5–2.5 Hz is 
typical. Slow SSW has maximal amplitude over frontal areas and ranges in duration 
from a few seconds to a few minutes or sub-continuous. The complexes typically 
consist of a spike (duration < 70 ms) or a sharp wave (70–200 ms), followed first 
by a positive deep and then by a negative wave (300–500 ms) [81]. Such stimuli, as 
eye opening, noise, calling the patient’s name, and pain, tend to decline the occur-
rence or terminate SSW [81]; on the other hand, relaxation and drowsiness favor 
their occurrence. Hyperventilation (HV) and intermittent photic stimulation (IPS) 
usually have little influence on the SSW activity.
Characteristic features during sleeping are:
• SSW discharges that are activated during slow sleep, with more marked 
tendency toward bilateral synchrony than in wakefulness.
• Bursts of high-amplitude generalized polyspikes and polyspike-waves.
Epilepsy - Advances in Diagnosis and Therapy
18
• “Paroxysmal fast activity” (PFA), which consists of sequences of rhythmic 
activity at 10–25 Hz and lasts for a few seconds (2–10 seconds) during NREM 
sleep. PFA is an essential diagnostic criterion.
These may be subclinical or accompanied by subtle change of axial muscle tone, 
which is detectable only by EMG electrodes as the ictal expression of a tonic seizure 
[81]. Interictal abnormalities and seizures decrease in REM sleep.
Focal abnormalities are usually present in patients with structural lesions; 
they are non-specific and depend on the underlying pathology: focal or multifocal 
spikes, spike-waves, polyspikes, slow waves, and focal bursts of rapid rhythms.
7.3.3 Ictal EEG
EEG pattern associated with typical seizures of LGS are:
• TS correspond to fast bilateral rhythmic spikes at 15–25 Hz. Amplitude is low 
at onset but increases as the discharge progresses, preponderating over the 
anterior areas and the vertex; occasionally diffuse slow waves follow after the 
end of the seizure [81].
• AA is concomitant with an irregular, diffuse, high-amplitude, more or less 
symmetric SSW that predominates over the frontal areas. AA may be difficult 
to differentiate from the interictal SSW pattern.
7.4 Etiology
LGS is classified as genetic, structural or metabolic, or unknown. Approximately 
70% of children with LGS have symptomatic. The underlying etiologies include a 
history of encephalitis, meningitis, tuberous sclerosis, brain malformations (e.g., 
cortical dysplasias), birth asphyxia, and trauma. LGS may also follow the diagnosis 
of West syndrome [23]. If unknown, then it can be either idiopathic or cryptogenic. 
Idiopathic refers to unknown etiology with the underlying cause being suspected 
as genetic; in contrast to cryptogenic, the underlying cause is also not known but 
is presumed to be structural or metabolic. The causative role of mutations in other 
genes (such as GABRB3, ALG13, SCN8A, STXBP1, DNM1, FOXG1, or CHD2) has 
been elucidated in recent exome studies or in case reports in patients with LGS 
without a history of infantile spasms [85].
7.5 Treatment and prognosis
The long-term prognosis varies and has not improved using new AED as com-
pared with earlier prescribed drugs [86].
Valproate is a first-choice drug, which has an effect in multiple seizure types 
including drop attacks; useful combinations are with clobazam, ethosuximide, 
lamotrigine, levetiracetam, topiramate, zonisamide, and rufinamide. We should 
avoid too many drugs as well as carbamazepine, oxcarbazepine, and vigabatrin, 
which may deteriorate some types of seizures. Felbamate carries the risk of aplastic 
anemia and hepatic failure and is used in exceptional cases [17].
Alternative treatment options for LGS include ketogenic diet, vagal nerve stimu-
lation (VNS) or thalamic electrical stimulation, and corpus callosotomy (CC) [87]. 
VNS and CC showed more than 50% reduction in seizure frequency in patients 
with LGS. A study showed that CC may be more beneficial than VNS only in “drop 
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attack” seizures [87], while another study did not show any significant difference 
between the two procedures [88].
Prognosis is typically poor with children having seizures into adulthood and 
75–95% with intellectual disability and behavioral and psychiatric disorders [82]. 
The risk of death is increased, compared with their peers of the same age, usually 
due to seizures and falls.
8.  Encephalopathy with electrical status epilepticus during slow sleep 
(ESES)
8.1 Overview
The term “electrical status epilepticus during sleeping” which was first described 
by Tassinari [1] refers to the EEG pattern (continuous spike-wave complexes exclu-
sively during non-rapid eye movement (NREM) sleep), with a spike-wave index 
accounting for at least 80–85% of slow sleep. Other concept, “continuous spikes and 
waves during sleeping” (CSWS) are considered synonymous of ESES, but indicates 
both, EEG features and clinical neuropsychological characteristics, of this EE [89, 90].
Encephalopathy with ESES is an EE characterized by seizures of various types and 
neurological deterioration in cognitive, motor, and behavioral areas. The encepha-
lopathy is caused by a prominent activation of epileptic abnormalities during NREM 
sleep [11]. Anti-seizure drugs, immune modulatory agents, and surgery [91] have 
been used to treat conditions associated with ESES. In spite of the long-term favor-
able outcome of epilepsy and ESES, the prognosis is protected because of the persis-
tence of severe cognitive and behavioral disturbances in about a half of the patients.
8.2 Seizures: symptoms and semiology
ESES syndrome is manifest with epilepsy and encephalopathy:
1. Epilepsy onset can fluctuate from 2 to 12 years, with a peak at about 4–5 years, 
and can appear before the identification of ESES pattern. Mostly, seizures are 
present during ESES, but in others there is no history of clinical seizures at any 
time. Semiology and frequency of seizures can vary; the presence of TS during 
sleeping excludes this diagnosis. Three groups of seizures type have been 
proposed: [11].
• Motor seizures, rare and nocturnal during the evolution of the syndrome
• Unilateral partial motor seizures or secondary TCGS, principally occurring 
during sleeping
• Rare nocturnal seizures in which AA develops during the course of ESES, 
often associated with negative myoclonus or atonic components leading to 
sudden falls
2. Encephalopathy manifests at the beginning or the worsening of neuropsy-
chological troubles, which include global cognitive regression and various 
degrees of language impairment (acquired aphasia), behavioral disorders 
(hyperactivity, attention deficits, and disturbances of personality), and 
deterioration of motor skills (dystonia, dyspraxia, ataxia, and negative 
myoclonus) [11].
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8.3 Electroencephalography
8.3.1 Background
During the wakefulness, it depends on the underlying etiology.
8.3.2 Interictal abnormalities
During the wakefulness, the EEG is characterized by focal or multifocal slow 
spikes, frequently intermixed with diffuse slow spikes and waves. In some children, 
the interictal EEG pattern may be similar to those observed in idiopathic focal 
epilepsies; in other cases, a background asymmetry, the presence of polyspikes or 
repetitive fast spikes, or other features may indicate underlying structural patholo-
gies (e.g., disorders of neuronal migration). These interictal EEG abnormalities may 
increase when ESES starts; in addition, diffuse bursts of 2–3-Hz spike-and-wave 
discharges may appear [11].
The typical EEG pattern consisted of continuous or sub-continuous slow spike-
and-waves, at 1.5–2.5 Hz, persisting through all NREM sleep; it appears immedi-
ately after patients fall asleep. This EEG pattern is commonly observed between 4 
and 14 years and develops 1 or 2 years after the onset of seizures.
The epileptic discharges can vary from mainly focal (frontal, centrotemporal, 
etc.) or multifocal to unilateral, or diffuse (occasionally with shifting from a 
unilateral to a diffuse pattern in the same patient). In the original description, 
a spike-wave index (SWIs), ranging from 85 to 100% and measured during 
overnight sleep EEG recording, was considered an essential feature for the 
diagnosis [92]; however, SWIs under 85% have been used for the diagnosis of 
ESES syndrome as well [11].
8.4 Etiology
The good outcome is the rule, independent of the etiology and is observed 
besides cortical malformations such as multilobar polymicrogyria. ESES syndrome 
has been associated with a few genes including neuroserpin/SRPX2 and ataxin 1/
ATX1 [23]; most recently, pathogenic de novo involves genes previously associated 
with autism (MDGA2 and SHANK3), seizures (GRIN2A), or language impairment 
(CDH13) [93]. Furthermore, SLC9A6 mutations have been found in patients with 
Christianson syndrome and CSWS [94]. The reason for manifestation of ESES in 
most patients is not known [23].
9. Landau-Kleffner syndrome (LKS)
9.1 Overview
The first description of the Landau and Kleffner syndrome (LKS) is due to 
William Landau and Frank Kleffner, who in 1957 reported six children with dif-
ferent types of seizures and acquired aphasia [2]. No other descriptions were made 
until the 1980s, when different authors described several new cases [95].
LKS is a type of ESES syndrome which manifests with an acquired epileptic 
aphasia (auditory agnosia) that occurs in the child with already developed age-
appropriate speech. Like ESES, LKS is characterized by epileptic EEG pattern 
particularly prominent during sleeping, with or without manifest clinical seizures. 
Although in the first descriptions LKS is not related to brain organic lesions, 
patients with LKS may have congenital or acquired brain lesions [11].
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9.2 Epileptic aphasia and seizure symptoms and semiology
LKS appear usually from 2 to 8 years of age; almost 60% of cases have epilepsy 
as the first symptom, while aphasia in the rest. Aphasia is a verbal auditory agnosia 
with a subacute onset, followed by rapid reduction of spontaneous speech, with 
perseverations, paraphasias, phonological errors, and verbal stereotypies; it can 
progress to mutism. Aphasia frequently has a course with remissions and exacer-
bations, usually related to quantitative variations of paroxysmal activity during 
sleeping [2, 96, 97]. The duration of the language disorder is very variable, though 
if it persists unchanged for more than a year, spontaneous recovery is rare. After a 
flexible time, aphasia stabilizes and regularly recovers before adulthood [98].
Although between 70 and 80% of patients present with epileptic seizures, these tend 
to be rare, sometimes a single seizure, which often occurs during sleeping. The seizures 
present clinical heterogeneity that includes subtle motor events such as ocular flicker, 
ocular deviation, simple motor focal seizures, AA, unilateral motor seizures, and, even-
tually, GTCS. CPSs are uncommon, while tonic seizures have never been reported. The 
course of the epilepsy is typically benign and seizures respond excellent to AED. Seizures 
eventually disappear over time, generally by about the age of 15 years [98].
9.3 Electroencephalography
9.3.1 Background
Normal.
9.3.2 Interictal paroxysmal abnormalities
9.3.2.1 Wakefulness
High-amplitude repetitive spikes and spike-waves with variable topography over 
time. Unilateral discharges are more common early in the course of LKS, habitually 
located in the temporal regions (>50% of the children) or in the parietal-occipital 
regions (around 30% of the children). Generalized spike-wave discharges have also 
been reported.
9.3.2.2 Sleep
At the beginning of sleep, epileptic discharges (ED) are also initiated. The 
ED can be partial, often on posterior temporal topography. Unilateral subclinical 
discharges can be detected alternating between both hemispheres. During the 
development of the disease, the EEG of the sleep will show a pattern of bilateral 
spike-wave activity, continuous or sub-continuous, during more than 85% of the 
NREM sleep time (ESES syndrome) [97]. LKS is a clinical subtype included in the 
wide spectrum of the clinical manifestations of ESES syndrome.
9.4 Etiology
In most patients the cause of LKS remains unknown. Autoimmune etiology has 
been suspected because of minor immunological irregularities reported in a num-
ber of patients and because of the response of LKS patients to immunotherapy [23]. 
Mutations in GRIN2A (16p13.2) have been reported as a major genetic cause of LKS 
and of the syndrome known as epileptic encephalopathy with continuous spikes 
and waves during slow-wave sleep (CSWS) [99]. Children with LKS have, most 
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of the time, a normal development until the start of language regression. Seizures 
of LKS often respond well to treatment with AED, but the speech and language 
impairments often persist, despite seizure control [100]. Occasional cases can be 
secondary to structural lesions such as benign temporal lobe tumors with improve-
ment after focal resection [101].
9.5 Treatment of encephalopathies with CSWS, including LKS
The aim of treatment is to stop seizures and eliminate epileptic discharges in the 
EEG; this will prevent and reverse cognitive decline in the idiopathic group and will 
prevent any further deterioration predetermined by the underlying pathology [18]. 
For it, early diagnosis and rapid appropriate and effective treatment are required.
Seizures in LKS are easier to control than seizures in CSWS. Many old and new 
AEDs are effective, depending on the seizure types. Valproate, sulthiame, benzodi-
azepines, ethosuximide, levetiracetam, lamotrigine, intravenous immunoglobulin 
(IVIG), corticosteroids, and ketogenic diet could be effective. The sodium channel-
blocking AEDs are contraindicated [17]. In some cases, with severe linguistic 
impairment, subpial intracortical transections have been successful.
10. Conclusion
Epileptic encephalopathy is defined as a condition where the epileptic activity 
itself may contribute to the severe neurological and cognitive impairment seen, 
over and above that would be expected from the underlying pathology alone. The 
epilepsy syndromes at high risk of this are a disparate group of conditions char-
acterized by epileptic seizures that are difficult to treat and developmental delay. 
Knowledge of the various severe epilepsy syndromes is vital to understanding the 
rationale for treatment.
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